EUCTR2004-005010-37-GB进行中（未招募）1 期
Enhancing cognition in bipolar disorder - Enhancing cognition in bipolar disorder
Suffolk Mental Health Partnerships Trust0 个研究点目标入组 20 人开始时间: 2005年6月13日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) All patients must be able to give informed written consent to participate in the study.
- •2) Aged 18 to 65
- •3) English should be spoken fluently
- •4) Participants should be literate and have normal or corrected to normal eyesight
- •5) All patients must have met DSM IV criteria for Bipolar I disorder in the past i.e. they must have had an episode of mania or a mixed affective state.
- •6) The Hamilton Depression Rating Scale and Young Mania Scale scores must be both be less than 8 for inclusion in the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) Patients should not currently fulfil criteria for mania, a mixed affective state, hypomania or major depression.
- •2) Patients should not score = 24 on the Mini-Mental State Examination (MMSE). All patients with a diagnosis of dementia will be excluded after review of case-records and/or discussion with their clinician.
- •3) Patients should not have a current diagnosis of alcohol or drug dependence based on DSM IV criteria.
- •4) Patients should not have a history of learning disability (or Wechsler test of Adult Reading score <90) or dyslexia
- •5) Patients with any known neurological illness (including narcolepsy) will be excluded
- •6) Patients with unstable medical illness that may affect cognition (untreated thyroid disease, type I diabetes mellitus or current treatment with steroids) will be excluded.
- •7) Patients who have received electroconvulsive therapy in the past three months will be excluded..
- •8) Patients taking herbal remedies such as St John’s Wort or Gingko Biloba will be excluded.
- •9) Subjects should not have moderate or severe hypertension. All patients should have blood pressure measurements within normal limits (i.e. systolic BP = 160 and diastolic BP = 90) prior to drug administration.
- •10) Patients will be excluded if they have a known history of angina or cardiac arrhythmias.
- •11) Subjects will be excluded if pregnant or breastfeeding
- •12) Patients taking phenytoin will be excluded because of a possible increase in plasma concentration.
- •13) Patients with a known hypersensitivity to modafinil or its excipients, or to the placebo will be excluded.
- •14) Patients who have participated in another clinical drug trial within the last three months will be excluded.
- •15) Female patients on an oral contraceptive (OC) will need to be counselled about the possibility that modafinil may reduce the effectiveness of the oral contraceptive. They will only be excluded if they are not willing to take the family planning advice recommendations in the BNF (March 49, 2005, page 402) (for the short term course of an enzyme inducing drug).
- •16) Patients should not have had any changes to their psychotropic drugs over the past 6 weeks.
研究者
相似试验
已完成
不适用
Enhancing cognition in bipolar disorderMental and Behavioural DisordersBipolar disorderISRCTN93360820Suffolk Mental Health Partnership NHS Trust (UK)20
招募中
2 期
Improvement of cognitive function in bipolar disorder by aripiprazole adjunct treatmentF31.7Bipolar affective disorder, currently in remissionDRKS00004316Bristol-Myers Squibb GmbH & Co. KGaA52
已完成
3 期
A Randomized Controlled Trial of Cognitive Remediation and D-cycloserine for Individuals With Bipolar DisorderBipolar DisorderNCT01934972University of Arizona30
Unknown
不适用
Assessment of Cognitive Functions in Bipolar PatientsBipolar DisorderNCT04091828Assiut University72
已完成
4 期
Cognitive Enhancement in Bipolar DisorderBipolar DisorderNCT00597896Northwell Health50